BELLUS Health Inc.


BELLUS Health Inc. is a drug development company focused on rare diseases. Based in Laval, Quebec, the company has a portfolio of rare disease projects including KIACTA for AA amyloidosis (an orphan indication resulting in renal dysfunction that often rapidly leads to dialysis and death), clinical-stage Shigamab for Shiga toxin-producing Escherichia coli-related hemolytic uremic syndrome, and a research-stage project for AL amyloidosis. Its lead program, KIACTA, is partnered with global private equity firm Auven Therapeutics LLLP and is currently in phase 3 confirmation study.

streetwise book logo Streetwise Company Fact Sheet

2024/7/12 4:16:18